DEA Updates Synthetic Dissociative Scheduling: Diphenidine in Schedule I
The DEA synthetic dissociative scheduling update places diphenidine in Schedule I due to its high abuse potential and lack of accepted medical use. This reflects regulatory efforts to control emerging novel psychoactive substances. Clinicians should…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA emergency scheduling controlled substances update includes the temporary placement of 2-fluorodeschloroketamine in Schedule I. This reflects regulatory efforts to address emerging synthetic drugs with abuse potential. Clinicians should monitor…
Schedules of Controlled Substances: Placement of 3-MeO-PCP in Schedule I
The DEA has placed 3-MeO-PCP in Schedule I due to its high abuse potential and lack of accepted medical use. This regulatory action addresses emerging synthetic drugs like 3-MeO-PCP that pose public health risks. Clinicians should be aware of 3-MeO-PCP…
Schedules of Controlled Substances: DEA Synthetic Cannabinoids Schedule I Placement 2026
The DEA synthetic cannabinoids Schedule I placement 2026 update includes MDMB-4en-PINACA due to its high abuse potential and health risks. This scheduling reflects efforts to regulate emerging synthetic cannabinoids posing public health challenges.…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products to Schedule III
The DEA rescheduling cannabis products from Schedule I to Schedule III marks a pivotal regulatory change. This shift applies to FDA-approved cannabis-derived medications, easing prescribing and research barriers. Clinicians should note this change…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA synthetic cannabinoids schedule I placement 2026 marks a critical regulatory update addressing new designer drugs. This action highlights the growing concern over synthetic cannabinoids' abuse potential and clinical risks. Clinicians should be…
Schedules of Controlled Substances: DEA Update on Synthetic Cannabinoids
The DEA synthetic cannabinoids schedule I placement update designates cumyl-pegaclone as a high-risk substance with no accepted medical use. This update highlights ongoing challenges in regulating novel synthetic cannabinoids. Clinicians should be aware…
Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA synthetic ketamine schedule I placement of 2-fluorodeschloroketamine reflects urgent regulatory action on novel psychoactive substances. This temporary scheduling addresses abuse potential and lack of accepted medical use. Clinicians should stay…
Diphenidine Scheduling Update Under DEA Controlled Substances Act
The diphenidine DEA scheduling update marks a significant regulatory action under the Controlled Substances Act. This update highlights the evolving policy landscape for synthetic dissociative drugs. Understanding this scheduling update is critical for…
Policy Watch: DEA Scheduling Actions on Synthetic Drugs — June 18, 2026
This update covers DEA scheduling synthetic drugs 2026 with six key regulatory actions impacting clinical research and cannabis-related therapies. The DEA placed several novel synthetic substances into Schedule I, affecting legal status and research…